THE ROLE OF ANTICOAGULANTS AND ANTIPLATELETS IN PROPHYLAXIS AND/OR TREATMENT OF SEVERE SARS-COV-2 INFECTION
-
Wessam F. El-Hadidy
Department of Pharmacology and Experimental Therapeutics, Medical Research Institute, Alexandria University. Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University in Alexandria, Egypt.
-
Asmaa A. Khalifa
Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University in Alexandria, Egypt.
Keywords:
Anticoagulants, antiplatelets, coronavirus, fibrinolytics, severe acute respiratory syndrome, SARAS-COV-2Abstract
Severe acute respiratory syndrome coronavirus-2(SARAS-COV-2) was reported firstly in China by the end of 2019 then disseminated vigorously worldwide and in 2020 reported by WHO as pandemic disease. It is associated by many symptoms, however; high incidence of thrombotic events was strongly correlated with SARAS-COV-2. Exploring anticoagulants to be added as thromboprophylaxis for Covid 19 patients become a must. Many options for thromboprophylaxis are available including anticoagulants, antiplatelets and fibrinolytics which were illustrated in this mini review.
Peer Review History:
Received 1 December 2020; Revised 5 January 2021; Accepted 12 February; Available online 15 March 2021
Academic Editor: Essam Mohamed Eissa
, Beni-Suef University, Egypt, dressamceutics@yahoo.com
Reviewer(s) detail:
Dr. Cecilia Nwadiuto Amadi, University of Port Harcourt, Port Harcourt Rivers State, Nigeria, cnamadi@rocketmail.com
Dr. A.A. Mgbahurike, University of Port Harcourt, Nigeria, amaka_mgbahurike@yahoo.com
Downloads
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.